1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd

512.70
INR
+1.85
(+0.36%)
48.16EPS
12.95P/E
12.49BMarket Cap
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
(National Stock Exchange of India)

Recent

price

512.70

P/E

ratio

12.95

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
108.21
115
119.37
129.05
163.13
245.33
196.66
177.5
178.43
188.42
207.07
233.75
252.1
285.19
307.17
330.65
346.66
Revenue per Share
2.55
3.14
5.92
6.53
9.2
14.52
15.79
17.31
24.36
25.72
31.08
34.63
36.4
46.58
41.11
43.88
48.16
Basic EPS, GAAP
-28.83
-3.21
-21.09
0.44
12.64
6.79
4.17
8.37
18.95
33.86
30.21
15.28
12.47
11.78
36.83
40.1
- -
Free Cash Flow per Basic Share
0.97
0.7
0.7
0.7
0.7
1.21
1.1
1.44
1.81
3.62
- -
1.5
1.5
1.5
1.8
1.8
- -
Dividend per Share
47.1
49.53
54.75
60.58
68.24
88.07
96.19
112.11
156.54
156.54
182.99
216.12
250.86
295.98
335.34
378.25
- -
Book Value per Share
46.78
46.76
51.73
57.73
65.01
82.26
91.39
107.33
151.75
151.75
182.79
215.93
250.72
295.82
335.12
377.79
- -
Tangible Book Value per Share
16
16
16
16
16
16
18
20
20
20
20
20
20
20
20
20
20
Basic Weighted Avg Shares
1,765
1,876
1,947
2,105
2,661
4,002
3,503
3,550
3,569
3,768
4,147
4,682
5,050
5,712
6,152
6,623
6,942
Sales/Revenue/Turnover
4.73
6.36
7.57
8.55
8.47
9.84
12.13
13.41
17.24
16.15
19.24
18.88
15.98
15.69
14.55
12.95
12.45
Operating Margin (%)
17
19
26
35
46
49
55
61
67
73
76
81
92
106
129
145
149
Depreciation Expense
42
51
97
107
150
237
281
346
487
514
623
694
729
933
823
879
965
Net Income, GAAP
32.54
30.01
16.25
15.63
24.21
28.02
24.64
25.08
21.63
23.45
25.65
27.71
27.45
23.67
24.58
23.98
24.52
Effective Tax Rate (%)
2.36
2.73
4.96
5.06
5.64
5.92
8.03
9.75
13.65
13.65
15.01
14.81
14.44
16.33
13.38
13.27
13.89
Profit Margin (%)
427
167
49
180
667
429
902
1,134
1,824
1,824
2,329
2,624
2,951
3,455
3,937
4,720
- -
Working Capital
41
143
171
192
255
194
124
69
8
8
1
- -
- -
- -
- -
- -
- -
LT Debt
768
851
935
1,025
1,142
1,439
1,927
2,245
3,135
3,135
3,664
4,329
5,025
5,928
6,717
7,576
- -
Total Equity
5.6
6.32
7.93
9.04
9.47
12.66
13.04
12.77
15.68
14.13
17.18
15.57
12.33
12.43
10.63
9.11
- -
Return on Invested Capital (%)
4.13
3.82
6.29
9.69
11.58
14.03
13.52
13.99
16.92
16.5
18.42
17.46
15.77
17.12
13.13
12.31
- -
Return on Capital (%)
6.4
6.5
11.36
11.33
14.29
18.58
16.74
16.62
18.13
16.43
18.33
17.36
15.59
17.04
13.02
12.3
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
44
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
9,693
11,316
12,489

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
5,831
- -
Cash, Cash Equivalents & STI
- -
2,407
- -
Accounts Receivable, Net
- -
1,614
- -
Inventories
- -
801
- -
Total Current Liabilities
- -
1,110
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
44
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.66%
12.8%
Free Cash Flow
43.51%
29.62%
8.88%
Net Income, GAAP
14.87%
7.9%
6.74%
Sales/Revenue/Turnover
5.43%
9.84%
7.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,473
1,612
1,466
1,682
6,152
2026
1,541
1,634
1,663
1,873
6,623
2027
1,773
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
11.82
13.15
10.37
5.78
41.11
2026
13.82
9.98
14.28
5.81
43.88
2027
18.09
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.8
2026
- -
- -
- -
- -
1.8
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Lincoln Pharmaceuticals Limited (LINCOLN.NS), headquartered in Ahmedabad, Gujarat, India, manufactures, markets, and distributes a broad portfolio of pharmaceutical formulations. Founded in 1979 as a partnership and converted to a public limited company in 1995, the company produces tablets, capsules, dry syrups, ointments, creams, sterile ophthalmic ointments, small volume parenteral injectables including dry powder injections, liquid vials, ampoules, eye/ear drops, and oral liquids across therapeutic categories such as anticold, antibiotics, otolaryngology, pain management, gastro-intestinal, anti-malarial, anti-fungal, corticosteroids, cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory, and dyslipidemic agents; it offers both branded generics and specific brands like LENOCARB antacid suspension, PA12 long-acting paracetamol tablets, TRIXON cefixime products, ARH anti-malarial kits, VIVIAN diclofenac gel, and ISL Granules ayurvedic granules. Lincoln operates manufacturing facilities in Khatraj, Naroda, and Mehsana in Gujarat compliant with WHO-cGMP and ISO 9001:2015 standards, with in-house R&D and testing labs; it serves the domestic Indian market and exports to approximately 60 countries across Europe, Canada, Latin and North America, Africa, Asia Pacific, and South East Asia. Recent developments include the 2021-22 amalgamation of its subsidiary Lincoln Parenteral Limited to streamline operations, the 2022 acquisition of a Mehsana plant for cephalosporin production with commercial commencement in fiscal 2025, receipt of EU GMP approval and Australian TGA nod for select products, and launches of new offerings such as Vitamin C+ zinc tablets alongside ongoing expansion into US and UK markets.